A Randomized Double-Blind Placebo-Controlled Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults with Symptomatic Genital HSV-2 Infection (HSV2-201)
-
- STATUS
- Not Recruiting
Summary
The purpose of this study is to test a therapeutic genital herpes vaccine named VCL-HB01 for its safety and effectiveness against HSV-2. The study will determine what effect the vaccine has on people and their natural defense system to reduce, if not prevent, genital herpes outbreaks (also called genital herpes recurrences).
Description
The purpose of this study is to evaluate the safety and efficacy of 4 doses of VCL-HB01, a therapeutic HSV plasmid DNA vaccine, in HSV-2-seropositgive adults with a reported history of 4 to 9 recurrences in the prior year in the absence of suppressive antiviral therapy or in the year prior to starting suppressive antiviral therapy.
Details
| Condition | herpes simplex virus type 2,genital herpes |
|---|---|
| Age | 18years - 50years |
| Clinical Study Identifier | TX6994 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.